Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [Phase 1, Phase 2]
Clinical trial update for IMM01 combined with azacitidine in acute myeloid leukemia and myelodysplastic syndromes, currently in Phase 1 and …
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs [Phase 3]
Phase 3 trial evaluating guadecitabine (SGI-110) vs treatment choice in adults with myelodysplastic syndromes or chronic myelomonocytic leuk…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders [Phase 2]
Phase 2 clinical trial update on donor peripheral stem cell transplantation for patients with advanced hematologic cancers and related disor…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial update evaluating a conditioning regimen of Helical Tomotherapy with fludarabine phosphate and melphalan foll…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT [Phase 2]
A Phase 2 clinical trial evaluating a conditioning regimen combining venetoclax, azacytidine, and a modified BUCY approach for patients with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders [NA]
This clinical trial update reports on allogeneic hematopoietic cell transplantation from matched unrelated donors in patients with advanced …
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
A completed clinical trial study (MDS-TAO) focused on transplantation outcomes in myelodysplastic syndromes with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS [Phase 1, Phase 2]
Phase 1/2 trial of TP-0184 for anemia in adults with IPSS-R low or intermediate-risk myelodysplastic syndromes was terminated; results poste…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [Phase 3]
This clinical trial update reports results from a Phase 3 study of ivosidenib combined with azacitidine versus placebo in previously untreat…
-
FDA approval · 2023-03-16FDA Approved: DEFERASIROX — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Deferasirox from Camber Pharmaceuticals, authorizing a generic product under ANDA 216229.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT [Phase 2, Phase 3]
Phase 2/Phase 3 trial assessing CD45RA-depleted T-cell infusion to prevent infections after TCRab/CD19-depleted allogeneic hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing thymoglobulin to alemtuzumab in patients undergoing allogeneic stem cell transplantation has been compl…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Panobinostat Maintenance After HSCT fo High-risk AML and MDS [Phase 3]
Phase 3 trial update on panobinostat maintenance after stem cell transplant in high-risk AML and MDS was terminated.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of ProTmune for allogeneic hematopoietic cell transplantation in adults with hematologic malignancies completed; results pos…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
Phase 1/2 trial investigating cytokine-induced memory-like NK cells in patients with acute myeloid leukemia or myelodysplastic syndrome; stu…
-
FDA approval · 2022-12-30FDA Approved: AZACITIDINE — Original Application (Eugia US LLC)
FDA approved the original application (ANDA) for azacitidine as a generic product, with Eugia US LLC listed as the manufacturer.
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating clofarabine, melphalan, and thiotepa followed by donor stem cell transplant for high-risk hematologic …
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation [Phase 3]
A Phase 3 randomized trial comparing Fludarabine and Busulfan versus Fludarabine, Busulfan plus Total Body Irradiation in patients with myel…
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [Phase 2]
Phase 2 trial update on conditioning regimens for transplantation of unrelated donor umbilical cord blood in patients with hematologic malig…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]
Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study…
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) [Phase 2]
Phase 2 clinical trial evaluating hypomethylating effects of freeze-dried black raspberries in patients with myelodysplastic syndromes.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS [Phase 3]
Phase 3 trial comparing NiCord (omidubicel) stem cell transplantation to standard umbilical cord blood in patients with hematologic malignan…
-
CLINICAL_TRIALS trial_result · 2022-10-21Clinical Trial Update: A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS [Phase 1, Phase 2]
A phase 1b/2 trial evaluating alvocidib in combination with decitabine or azacitidine in myelodysplastic syndromes was terminated; results w…
-
FDA approval · 2022-09-23FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.